# Alzheimer's Disease: Clinical Investigation and Neuroimage Studies Including 18F-PM-PBB3 and 18F-florbetapir (AV-45) PET Examination

> **NCT04305210** · PHASE2 · UNKNOWN · sponsor: **Chang Gung Memorial Hospital** · enrollment: 70 (estimated)

## Conditions studied

- Alzheimer's Disease

## Interventions

- **DRUG:** F-18 PMPBB3
- **DRUG:** 18F-florbetapir

## Key facts

- **NCT ID:** NCT04305210
- **Lead sponsor:** Chang Gung Memorial Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-12-01
- **Primary completion:** 2021-01-23
- **Final completion:** 2021-01-23
- **Target enrollment:** 70 (ESTIMATED)
- **Last updated:** 2020-03-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04305210

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04305210, "Alzheimer's Disease: Clinical Investigation and Neuroimage Studies Including 18F-PM-PBB3 and 18F-florbetapir (AV-45) PET Examination". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT04305210. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*